Dosing & Timing

Boswellia and AKBA dosing logic, clinical trial ranges, food timing, and formulation considerations

Dosing Boswellia in oncology is more complex than simply choosing a high milligram label.

The key variables are AKBA content, extract standardisation, and whether the product is taken with food.

Core issue

Boswellia products differ widely in:

AKBA percentage
Total boswellic acids
Overall extract quality
Formulation type

Visit the Sourcing Quality Boswellia page for detailed information on two trusted formulas available worldwide.

General dosing logic

Clinical and integrative use often falls roughly into these bands:

general adjunctive support: around 1,500–2,400 mg/day of standardised extract
human breast-cancer window trial anchor: 2,400 mg/day of BosPure® for about 2 weeks before surgery
brain tumour / radiation-oedema use: typically around 3,600–4,500 mg/day in divided doses, with 4,200 mg/day as the clearest pilot-trial anchor

The strongest practical dosing literature for Boswellia is actually in brain tumours, not breast cancer.

The clearest supportive-care anchor is the Kirste pilot randomised trial in patients receiving brain radiotherapy.

Key details:

setting: brain tumours with radiation-related cerebral oedema
study design: prospective, randomised, placebo-controlled, double-blind pilot trial
trial dose: 4,200 mg/day in divided doses
main result: greater MRI-visible oedema reduction than placebo
clinical signal: some neurologic improvement and steroid-sparing benefit
tolerability: 4,200 mg/day was reported as well tolerated

A later 2025 review of Boswellia for radiation-induced CNS toxicity summarised that most clinical neuro-oncology use falls around 3,600 to 4,500 mg/day in divided doses.

That makes the brain-tumour literature the clearest example of higher-dose supervised Boswellia use in oncology.

A 2024 abstract described two patients who accidentally took about 42,000 mg/day rather than 4,200 mg/day and were still surprisingly tolerant.

That is not a recommended dose.

It is an anecdotal signal only.

Human dosing example — 2024 breast-cancer window trial

The clearest AKBA-standardised Boswellia dosing anchor in human oncology is the 2024 Phase Ia breast-cancer window trial.

Key details:

product used: BosPure® Boswellia serrata extract
capsule strength: 400 mg
standardisation: 10% AKBA
trial dose: 2 capsules three times daily with food
total daily extract: 2,400 mg/day
estimated daily AKBA: about 240 mg/day
duration: the short period between biopsy and surgery, usually around 2 weeks

Key findings:

tumour proliferation marker Ki-67 fell significantly versus control
the drop was about 13–14%
no significant increase in apoptosis markers was seen
tolerability was good, with no serious treatment-related adverse events reported

This does not prove Boswellia treats breast cancer.

It does give a useful real-world reference point for how one human oncology study dosed a standardised AKBA-containing extract.

AKBA comparison examples for published dose anchors

The BosPure® breast-cancer trial delivered about 240 mg AKBA per day.

That makes daily AKBA exposure a more useful comparison point than raw Boswellia milligrams alone.

Using the product details currently listed on this site:

To approximate the breast-cancer trial anchor of 240 mg AKBA/day:
- Boswellia MEGA AKBA Liposomal — about 4 capsules/day
- Inflasanum — about 2 capsules/day reaches about 360 mg AKBA/day, which is already above that anchor
To approximate a 4,200 mg/day brain-oedema regimen using a 10% AKBA-style extract, the rough equivalent would be about 420 mg AKBA/day
- Boswellia MEGA AKBA Liposomal — about 7 capsules/day
- Inflasanum — about 3 capsules/day reaches about 540 mg AKBA/day, which is above that rough comparison point

Not all brain-oedema studies reported AKBA standardisation in the same way.

So the 420 mg AKBA/day comparison is only a rough translation, not a strict dose conversion.

Higher-AKBA products may still reach research-style targets with fewer capsules and less total extract.

Timing principles

Take Liposomal Boswellia 20 minutes before food with a 200ml glass of water
Divided doses usually make more sense because of the modest half-life
If combining with other CYP-active compounds, spacing them out may be warranted in some instances

Practical takeaway

The better Boswellia dosing question is not just How much Boswellia?

It is:

How much standardised extract
How much AKBA
How it is being taken and absorbed
and what the clinical goal actually is

For the brain-tumour supportive-care data behind the higher-dose anchor, see Glioblastoma & Brain Tumours.

For the human breast-cancer data behind the lower AKBA-standardised anchor, see Breast Cancer.

For high-AKBA product comparison, see Sourcing Quality Boswellia.

For safety review, see Safety & Interactions.

Key References

Enhanced Bioavailability of Boswellic Acid by Piper longum
https://pmc.ncbi.nlm.nih.gov/articles/PMC7770183/

Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors
https://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.25945

Boswellia serrata for cerebral radiation necrosis after radiosurgery for brain metastases
https://www.redjournal.org/article/S0360-3016(25)00153-1/fulltext

The anti-proliferative effects of a frankincense extract in a window of opportunity Phase Ia clinical trial for patients with breast cancer
https://pmc.ncbi.nlm.nih.gov/articles/PMC10959833/

The anti-proliferative effects of a frankincense extract in a window of opportunity Phase Ia clinical trial for patients with breast cancer
https://pubmed.ncbi.nlm.nih.gov/38194131/

Jump to another Boswellia page

Core pages

Mechanism deep dives

Practical pages

Cancer-type pages

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.